Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. These include coronary stents, carotid stents, peripheral stents, bioresorbable or bioabsorbable stents, and renal stents. News included clinical trial data and new technology advances in stents.

Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025
News | Stents | August 21, 2019

August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the...

TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | August 15, 2019

August 15, 2019 — The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late...

Endovascular-first Approach Equal to Open Surgery in Avoiding Amputation for Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | August 01, 2019

August 1, 2019 — Less-invasive procedures to open severely clogged...

TCAR Achieves Favorable Outcomes Versus Carotid Endarterectomy in CAD Patients
News | Stents Carotid | June 13, 2019

June 13, 2019 — Silk Road Medical Inc. announced the presentation of...

Illustration showing the self-expanding deployment of the Boston Scientific Vici venous stent in the iliofemoral vein.

Illustration showing the self-expanding deployment of the Vici stent in the iliofemoral vein. 

Technology | Venous Therapies | May 06, 2019

May 6, 2019 — The U.S Food and Drug Administration (FDA) has cleared the Boston Scientific Vici Venous Stent System...

FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019

April 18, 2019 — The U.S. Food and Drug Administration published a draft guidance titled, “...

Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019

April 15, 2019 – Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack...

BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019

April 15, 2019 — Biotronik began its U.S. commercial launch of the PK Papyrus covered coronary stent system for use...

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard...

The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous Stent System intended to treat narrowed iliofemoral veins.
Technology | Venous Therapies | April 03, 2019

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo...

Medtronic's Resolute Integrity Zotarolimus-eluting Coronary Stent System received an additional U.S. Food and Drug Administration (FDA) indication for treatment of de novo chronic total occlusion (CTO) lesions.
Technology | April 03, 2019

April 3, 2019 — Medtronic's Resolute Integrity Zotarolimus-eluting Coronary Stent System received an additional U.S...

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor

February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent...

Two devices where safety is being called into question based on clinical data that is being questioned. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Blog | Cath Lab | February 20, 2019

Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor

In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...

The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor

There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years...

Overlay Init